☰

Anamika Basu - Publications

Affiliations: 
Loma Linda University, Loma Linda, United States 
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kulkarni A, Gayathrinathan S, Nair S, Basu A, Al-Hilal TA, Roy S. Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities. Cells. 11. PMID 35954293 DOI: 10.3390/cells11152448  0.318
2018 Woods-Burnham L, Cajigas-Du Ross CK, Love A, Basu A, Sanchez-Hernandez ES, Martinez SR, Ortiz-Hernández GL, Stiel L, Durán AM, Wilson C, Montgomery S, Roy S, Casiano CA. Glucocorticoids Induce Stress Oncoproteins Associated with Therapy-Resistance in African American and European American Prostate Cancer Cells. Scientific Reports. 8: 15063. PMID 30305646 DOI: 10.1038/S41598-018-33150-2  0.82
2018 Cajigas-Du Ross CK, Martinez SR, Woods-Burnham L, Durán AM, Roy S, Basu A, Ramirez JA, Ortiz-Hernández GL, Ríos-Colón L, Chirshev E, Sanchez-Hernandez ES, Soto U, Greco C, Boucheix C, Chen X, et al. RNA sequencing reveals upregulation of a transcriptomic program associated with stemness in metastatic prostate cancer cells selected for taxane resistance. Oncotarget. 9: 30363-30384. PMID 30100995 DOI: 10.18632/Oncotarget.25744  0.77
2018 Woods-Burnham L, Ross CKC, Basu A, Sanchez ES, Love A, Casiano CA. Abstract 5043: Glucocorticoids trigger GR-mediated expression of the chemoresistance-associated oncoproteins LEDGF/p75 and Clusterin: Implications for prostate cancer health disparities Cancer Research. 78: 5043-5043. DOI: 10.1158/1538-7445.Am2018-5043  0.888
2017 Woods-Burnham L, Basu A, Cajigas-Du Ross CK, Love A, Yates C, De Leon M, Roy S, Casiano CA. The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models. The Prostate. PMID 29030865 DOI: 10.1002/Pros.23437  0.846
2017 Ríos-Colón L, Cajigas-Du Ross CK, Basu A, Elix C, Alicea-Polanco I, Sanchez TW, Radhakrishnan V, Chen CS, Casiano CA. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget. PMID 28212536 DOI: 10.18632/Oncotarget.15323  0.866
2017 Mercado MV, Gómez-Bañuelos E, Navarro-Hernández RE, Pizano-Martinez O, Saldaña-Millán A, Chavarria-Avila E, Gonzalez-Rosas L, Andrade-Ortega L, Saavedra MA, Vera-Lastra OL, Jara LJ, Medrano-Ramírez G, Cruz-Reyes C, García-De la Torre I, Escarra-Senmarti M, ... ... Basu A, et al. Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms. Auto- Immunity Highlights. 8: 1. PMID 27896669 DOI: 10.1007/s13317-016-0089-7  0.601
2017 Woods-Burnham L, Love A, Ross CKC, Basu A, Stiel L, Montgomery S, Wilson C, Casiano CA. Abstract C43: Glucocorticoid-mediated upregulation of stress oncoproteins: Implications for prostate cancer health disparities Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-C43  0.873
2016 Basu A, Cajigas-Du Ross CK, Rios-Colon L, Mediavilla-Varela M, Daniels-Wells TR, Leoh LS, Rojas H, Banerjee H, Martinez SR, Acevedo-Martinez S, Casiano CA. LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis and Upregulates the Oxidoreductase ERP57/PDIA3/GRP58 in Prostate Cancer. Plos One. 11: e0146549. PMID 26771192 DOI: 10.1371/Journal.Pone.0146549  0.845
2016 Rios-Colon L, Sanchez TW, Elix CC, Alicea I, Basu A, Ross CD, Neamati N, Casiano CA. Abstract B06: Repositioning HIV-based small molecule inhibitors of the stress oncoprotein LEDGF/p75 to overcome prostate cancer resistance to taxane chemotherapy Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-B06  0.859
2015 Basu A, Woods-Burnham L, Ortiz G, Rios-Colon L, Figueroa J, Albesa R, Andrade LE, Mahler M, Casiano CA. Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: Preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2. Clinical Immunology (Orlando, Fla.). 161: 241-250. PMID 26235378 DOI: 10.1016/J.Clim.2015.07.014  0.791
2015 Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, Fritzler MJ, Casiano CA. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clinical and Experimental Medicine. PMID 26088181 DOI: 10.1007/S10238-015-0367-0  0.809
2015 Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: An Enigmatic Autoantigen at the Interface between Autoimmunity, AIDS, and Cancer. Frontiers in Immunology. 6: 116. PMID 25852687 DOI: 10.3389/Fimmu.2015.00116  0.766
2015 Colon LR, Elix C, Alicea I, Basu A, Ross CD, Sanchez T, Neamati N, Casiano C. Abstract 5411: Repositioning HIV-based small molecule inhibitors of the stress survival oncoprotein LEDGF/p75 to overcome taxane resistance in prostate cancer Cancer Research. 75: 5411-5411. DOI: 10.1158/1538-7445.Am2015-5411  0.872
2014 Colon LR, Elix C, Basu A, Sanchez TW, Neamati N, Casiano CA. Abstract 775: Targeting the stress survival oncoprotein LEDGF/p75 to overcome prostate cancer resistance to taxane therapy Cancer Research. 74: 775-775. DOI: 10.1158/1538-7445.Am2014-775  0.88
2014 Basu A, Ortiz-Hernández GL, Casiano CA. Abstract 3619: Specificity of the human autoantibody response against the stress oncoprotein LEDGF/p75 Cancer Research. 74: 3619-3619. DOI: 10.1158/1538-7445.Am2014-3619  0.851
2013 Rios-Colon L, Basu A, Elix C, Casiano CA, León MD. Abstract 892: The stress oncoprotein LEDGF/P75 promotes selective resistance to multiple chemotherapeutic drugs in prostate cencer cells. Cancer Research. 73: 892-892. DOI: 10.1158/1538-7445.Am2013-892  0.852
2013 Basu A, Cajigas C, Medina B, Rojas H, Banerjee H, Mediavilla-Varela M, Leoh L, Casiano C. Abstract 3117: Overexpression of the stress transcription co-activator LEDGF/p75 contributes to the upregulation of the stress protective genes HSP27, ERp57 and CYGB in prostate cancer. Cancer Research. 73: 3117-3117. DOI: 10.1158/1538-7445.Am2013-3117  0.858
2012 Basu A, Rojas H, Banerjee H, Cabrera IB, Perez KY, De León M, Casiano CA. Expression of the stress response oncoprotein LEDGF/p75 in human cancer: a study of 21 tumor types. Plos One. 7: e30132. PMID 22276150 DOI: 10.1371/Journal.Pone.0030132  0.764
2012 Leoh LS, van Heertum B, De Rijck J, Filippova M, Rios-Colon L, Basu A, Martinez SR, Tungteakkhun SS, Filippov V, Christ F, De Leon M, Debyser Z, Casiano CA. The stress oncoprotein LEDGF/p75 interacts with the methyl CpG binding protein MeCP2 and influences its transcriptional activity. Molecular Cancer Research : McR. 10: 378-91. PMID 22275515 DOI: 10.1158/1541-7786.Mcr-11-0314  0.828
2012 Basu A, Drame A, Muñoz R, Gijsbers R, Debyser Z, De Leon M, Casiano CA. Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator LEDGF/p75 in prostate cancer cells. The Prostate. 72: 597-611. PMID 21796653 DOI: 10.1002/Pros.21463  0.785
2012 Basu A, Ríos-Colón L, Nishikawa C, Elix C, Nguyen L, Djeu J, León MD, Casiano C. Abstract 775: Targeting the transcriptional coactivator LEDGF/p75 to overcome chemoresistance in prostate cancer Cancer Research. 72: 775-775. DOI: 10.1158/1538-7445.Am2012-775  0.868
2012 Ríos-Colón L, Basu A, Cajigas C, Elix C, Casiano CA. Abstract B76: Circumventing chemoresistance as a strategy to reduce the mortality disparities associated with advanced prostate cancer. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B76  0.875
2011 Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. The Prostate. 71: 755-65. PMID 21031435 DOI: 10.1002/Pros.21292  0.852
2011 Basu A, Drame A, Leon MD, Casiano CA. Abstract 2092: Pathway specific gene profiling analysis reveals potential target genes of the stress oncoprotein LEDGF/p75 in prostate cancer cells Cancer Research. 71: 2092-2092. DOI: 10.1158/1538-7445.Am2011-2092  0.816
2011 Leoh LS, Mediavilla-Varela M, Basu A, Daniels TR, Martinez S, Pacheco FJ, Padilla A, Asuelime G, Rios-Colon L, Leon MD, Casiano CA. Abstract 2083: The stress oncoprotein LEDGF/p75 attenuates oxidative stress-induced necrosis but not apoptosis in prostate cancer cells Cancer Research. 71: 2083-2083. DOI: 10.1158/1538-7445.Am2011-2083  0.813
2010 Basu A, Rojas H, Banerjee H, Cabrera IB, Perez KY, Leon MD, Casiano CA. Abstract 4667: Elevated expression of the stress oncoprotein LEDGF/p75 in major human cancers Cancer Research. 70: 4667-4667. DOI: 10.1158/1538-7445.Am10-4667  0.745
2010 Basu A, Mediavilla-Varela M, Martinez S, Rojas H, Banergee H, Roy S, Lilly MB, Leon MD, Casiano CA. Abstract 2715: Peroxiredoxin 3: A potential biological determinant of prostate cancer health disparities Cancer Research. 70: 2715-2715. DOI: 10.1158/1538-7445.Am10-2715  0.851
2010 Basu A, Banerjee H, Rojas H, Martinez S, Mediavilla-Varela M, Sourav R, Jia Z, Mercola D, Lilly MB, Leon MD, Casiano CA. Abstract A108: Differential expression of peroxiredoxins in prostate cancer: Ethnic differences in the association of PRDX3 expression with clinical outcomes Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A108  0.852
Show low-probability matches.